TherapeuticsMD, Inc. (TXMD) - Q1 2026 Filing Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2026. TherapeuticsMD, Inc. operates as a pharmaceutical royalty company following a strategic transformation in December 2022. The company no longer conducts commercial operations; instead, it generates revenue through royalties and milestone payments from partners (primarily Mayne Pharma) commercializing its licensed products (IMVEXXY, BIJUVA, ANNOVERA, and prenatal vitamins). Former commercial operations are reported as discontinued operations.
Key Financial Metrics
| Metric | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Revenue (License) | $724,000 | $393,000 |
| Net Income (Loss) | $95,000 | $(653,000) |
| Operating Loss | $(723,000) | $(1,281,000) |
| Cash and Cash Equivalents | $8,419,000 | $5,745,000 |
| Net Cash Provided by Operating Activities | $944,000 | $699,000 |
| Total Assets | $37,581,000 | $37,656,000 |
| Total Liabilities | $10,608,000 | $10,780,000 |
| Stockholders' Equity | $26,973,000 | $26,876,000 |
Note: All figures in thousands except per share data. The company reported a net income of $0.01 per share (basic and diluted) for Q1 2026, compared to a loss of $0.06 per share in Q1 2025.
Material Changes vs. Prior Period
- Revenue Growth: License revenue increased by 84% ($331,000) year-over-year, driven by changes in sales of licensed products.
- Profitability Turnaround: The company returned to profitability, reporting net income of $95,000 compared to a net loss of $653,000 in the prior year. This was primarily due to increased revenue, higher sublease income ($517,000 vs. $410,000), and the absence of an $88,000 patent write-off recorded in Q1 2025.
- Expense Reduction: Total operating expenses decreased by 13.6% to $1,447,000, largely due to lower professional fees and share-based compensation costs.
- Liquidity Improvement: Cash and cash equivalents increased by approximately $936,000 during the quarter, resulting in a total cash balance of $8.4 million.
Outlook, Risks, and Contingencies
Going Concern Uncertainty: Management has raised substantial doubt about the company's ability to continue as a going concern for the next twelve months. This is due to reliance on royalty income, potential declines in partner sales, and the uncertainty of resolving significant legal disputes. The company may need to raise additional capital, which could result in dilution.
Legal Proceedings (Mayne Pharma):
- Mayne Lawsuit: Filed in April 2025, seeking damages for breach of contract and fraudulent inducement regarding net working capital allowances. A magistrate judge recommended in March 2026 to stay the lawsuit while parties submit net working capital claims to dispute resolution. Some claims were recommended for dismissal, while others remain.
- Mayne Countersuit: Filed in May 2025 by Mayne Pharma. A magistrate judge recommended dismissing the fraudulent inducement claim but denying the dismissal of other claims.
- Financial Impact: The company cannot reasonably estimate a range of loss for these matters and has not accrued additional liabilities, though the outcome could be material.
Patent Litigation: Ongoing litigation against Teva Pharmaceuticals and Sun Pharma regarding generic versions of IMVEXXY. The company has capitalized $2.3 million in legal costs, which will be expensed if the litigation is unsuccessful.
Investor Verification Checklist
- Going Concern Status: Verify the company's ability to fund operations for the next 12 months given the explicit "substantial doubt" disclosure.
- Mayne Pharma Dispute Resolution: Monitor the status of the net working capital dispute resolution process and the final court rulings on the Mayne Lawsuit and Countersuit.
- Royalty Receivables: Assess the collectability of the $16.4 million in total royalty receivables (current and long-term), which are heavily dependent on Mayne Pharma's sales performance.
- Patent Litigation Outcome: Track the progress of the IMVEXXY patent infringement cases against Teva and Sun Pharma, as a loss could trigger immediate expensing of capitalized legal fees and reduce future royalty rates.
- Capital Raising Plans: Review any future filings regarding equity or debt financing, as the company may need to raise capital to maintain liquidity.